Johnson & Johnson Reports 2013 Second-Quarter Results:

            Johnson & Johnson Reports 2013 Second-Quarter Results:

Sales of $17.9 Billion increased 8.5% Versus 2012 Second Quarter;

Second-Quarter EPS was $1.33

Excluding Special Items, 2013 Second-Quarter EPS of $1.48 Increased 13.8%*

PR Newswire

NEW BRUNSWICK, N.J., July 16, 2013





NEW BRUNSWICK, N.J., July 16, 2013 /PRNewswire/ --Johnson & Johnson (NYSE:
JNJ) today announced sales of $17.9 billion for the second quarter of 2013, an
increase of 8.5% as compared to the second quarter of 2012. Operational
results increased 10.0% and the negative impact of currency was 1.5%.
Domestic sales increased 8.0%. International sales increased 9.0%, reflecting
operational growth of 11.8% and a negative currency impact of 2.8%. Sales
included the impact of the acquisition of Synthes, Inc., net of the
divestiture of the DePuy trauma business. Excluding this impact, worldwide
operational sales growth was 5.6%.

Net earnings and diluted earnings per share for the second quarter of 2013
were $3.8 billion and $1.33, respectively. The second quarter results
included the gain on the sale of the equity interest owned in Elan
Corporation, plc, as previously disclosed. Second quarter 2013 net earnings
included after-tax special items of approximately $0.5 billion, related to
litigation expenses, integration and transaction costs associated with the
acquisition of Synthes, Inc, and program costs associated with the DePuy
ASR^TM Hip. Second quarter 2012 net earnings included after-tax special items
of approximately $2.2 billion as shown in the accompanying reconciliation of
non-GAAP financial measures. Excluding these special items, net earnings for
the current quarter were $4.3 billion and diluted earnings per share were
$1.48, representing increases of 17.7% and 13.8%, respectively, as compared to
the same period in 2012.*

"Our strong second-quarter results reflect the progress we've made against our
near-term priorities of delivering on our financial commitments, restoring a
reliable supply of over-the-counter products to consumers, continuing the
successful integration of Synthes and building on the momentum in our
pharmaceutical business," said Alex Gorsky, Chairman and Chief Executive
Officer. "Our talented colleagues at Johnson & Johnson continue to bring
meaningful innovations to patients and consumers around the world and have
positioned us well to deliver sustainable growth."

The Company increased its earnings guidance for full-year 2013 to $5.40 -
$5.47 per share. The Company's guidance excludes the impact of special items.

Worldwide Consumer sales of $3.7 billion for the second quarter represented an
increase of 1.1% versus the prior year consisting of an operational increase
of 1.7% and a negative impact from currency of 0.6%. Domestic sales increased
1.0%. International sales increased 1.1%, which reflected an operational
increase of 2.0% and a negative currency impact of 0.9%.

Positive contributors to operational results were upper respiratory
over-the-counter medicines; TYLENOL^® and MOTRIN^® analgesics; international
sales of LISTERINE^® mouthwash; baby care products and women's sanitary
protection products.

Worldwide Pharmaceutical sales of $7.0 billion for the second quarter
represented an increase of 11.7% versus the prior year with operational growth
of 12.9% and a negative impact from currency of 1.2%. Domestic sales
increased 9.1%. International sales increased 14.1% which reflected an
operational increase of 16.5% and a negative currency impact of 2.4%.

Primary contributors to operational sales growth were REMICADE^® (infliximab)
and SIMPONI^® (golimumab), biologics approved for the treatment of a number
of immune-mediated inflammatory diseases; STELARA^® (ustekinumab), a biologic
approved for the treatment of moderate to severe plaque psoriasis; INVEGA^®
SUSTENNA^®/XEPLION^® (paliperidone palmitate), a once-monthly, long-acting,
injectable atypical antipsychotic for the acute and maintenance treatment of
schizophrenia in adults; VELCADE^® (bortezomib), a treatment for multiple
myeloma; PREZISTA^® (darunavir), a treatment for HIV; and sales of recently
launched products.

The strong sales results of recently launched products included ZYTIGA^®
(abiraterone acetate), an oral, once-daily medication for use in combination
with prednisone for the treatment of metastatic, castration-resistant prostate
cancer; XARELTO^® (rivaroxaban), an oral anticoagulant; and INCIVO^®
(telaprevir), a direct acting antiviral protease inhibitor, for the treatment
of genotype-1 chronic hepatitis C virus.

During the quarter, the U.S. Food and Drug Administration (FDA) approved
SIMPONI^® (golimumab) for the treatment of moderately to severely active
ulcerative colitis in adult patients who have demonstrated corticosteroid
dependence or who have had an inadequate response to or failed to tolerate
oral aminosalicylates, oral corticosteroids, azathioprine, or
6-mercaptopurine.

Additionally, the FDA granted Breakthrough Therapy Designation for daratumumab
for the treatment of patients with multiple myeloma who have received at least
three prior lines of therapy including a proteasome inhibitor (PI) and an
immunomodulatory agent (IMiD), or who are double refractory to a PI and IMiD.
Daratumumab is an investigational human CD38 monoclonal antibody licensed from
Genmab A/S.

In addition, a New Drug Application was submitted to the FDA under
Breakthrough Therapy Designation for the use of ibrutinib in previously
treated patients with chronic lymphocytic leukemia /small lymphocytic
lymphoma, and for use in previously treated patients with mantle cell
lymphoma.

Also during the quarter, a Marketing Authorization Application was submitted
to the European Medicines Agency seeking approval for simeprevir (TMC435).
Simeprevir is a new generation NS3/4A protease inhibitor, administered as one
150mg capsule once daily in combination with peginterferon alfa and ribavirin,
indicated for the treatment of genotype 1 or genotype 4 chronic hepatitis C in
adult patients with compensated liver disease (including cirrhosis), with or
without HIV-1 co-infection, who are treatment naive or who have failed
previous interferon therapy (pegylated or non-pegylated) with or without
ribavirin.

The Committee for Medical Products for Human Use of The European Medicines
Agency granted a positive opinion on two variations relating to the use
ofVELCADE^® (bortezomib). The first recommendation was for the use of
VELCADE^® as retreatment in adult patients who have previously responded to
treatment with the same medicine. The second recommendation was as induction
therapy in combination with dexamethasone or dexamethasone and thalidomide for
adult patients with previously untreated multiple myeloma that are eligible
for high-dose chemotherapy with haematological stem cell transplantation. In
addition, the European Commission approved a new twice daily (BID) dosing of
INCIVO^® (telaprevir), a direct acting antiviral protease inhibitor, in
combination with pegylated-interferon and ribavirin for naive and previous
treatment experienced patients.

A definitive agreement was signed in June to acquire Aragon Pharmaceuticals,
Inc., a privately-held, pharmaceutical discovery and development company
focused on drugs to treat hormonally-driven cancers. The acquisition includes
Aragon's androgen receptor antagonist program. Aragon's lead product
candidate is a second generation androgen receptor signaling inhibitor,
ARN-509, in Phase 2 development for castration resistant prostate cancer.

Worldwide Medical Devices and Diagnostics sales of $7.2 billion for the second
quarter represented an increase of 9.6% versus the prior year consisting of an
operational increase of 12.0% and a negative currency impact of 2.4%.
Domestic sales increased 9.8%. International sales increased 9.4%, which
reflected an operational increase of 13.7% and a negative currency impact of
4.3%. Sales included the impact of the acquisition of Synthes, Inc., net of
the divestiture of the DePuy trauma business. Excluding this impact, worldwide
operational sales growth was 0.5%.

Primary contributors to operational growth were sales from the acquisition of
Synthes, Inc., in the Orthopaedics business; Biosense Webster's
electrophysiology products in the Cardiovascular Care business; Vision Care's
1-Day ACUVUE^® TRUEYE and 1-Day ACUVUE^® MOIST^® disposable contact lenses;
and biosurgical and international sales of energy products in the Specialty
Surgery business.

During the quarter, the FDA granted Premarket Approval for the SEDASYS^®
System, the first computer-assisted personalized sedation system for healthy
patients undergoing sedation during routine colonoscopy and
esophagogastroduodenoscopy procedures.

About Johnson & Johnson
Caring for the world, one person at a time, inspires and unites the people of
Johnson & Johnson. We embrace research and science - bringing innovative
ideas, products and services to advance the health and well-being of people.
Our approximately 128,000 employees at more than 275 Johnson & Johnson
operating companies work with partners in health care to touch the lives of
over a billion people every day, throughout the world.

* Net earnings and diluted earnings per share excluding special items are
non-GAAP financial measures and should not be considered replacements for, and
should be read together with, the most comparable GAAP financial measures. A
reconciliation of these non-GAAP financial measures to the most directly
comparable GAAP financial measures is included in the financial schedules
accompanying this press release and can be found in the Investor Relations
section of the Company's website at www.investor.jnj.com.

Johnson & Johnson will conduct a conference call with financial analysts to
discuss this news release today at 8:30 a.m., Eastern Time. A simultaneous
webcast of the meeting for investors and other interested parties may be
accessed by visiting the Johnson & Johnson website at www.investor.jnj.com. A
replay and podcast will be available approximately two hours after the live
webcast by visiting www.investor.jnj.com.

Copies of the financial schedules accompanying this press release are
available at www.investor.jnj.com/historical-sales.cfm. These schedules
include supplementary sales data, a condensed consolidated statement of
earnings, reconciliation of non-GAAP financial measures, and sales of key
products/franchises. Additional information on Johnson & Johnson, including a
pharmaceutical pipeline of selected compounds in late stage development can be
found on the Company's website at www.jnj.com.

NOTE TO INVESTORS

(This release contains "forward-looking statements" as defined in the Private
Securities Litigation Reform Act of 1995. The reader is cautioned not to rely
on these forward-looking statements. These statements are based on current
expectations of future events. If underlying assumptions prove inaccurate or
unknown risks or uncertainties materialize, actual results could vary
materially from the expectations and projections of Johnson & Johnson. Risks
and uncertainties include, but are not limited to, general industry conditions
and competition; economic factors, such as interest rate and currency exchange
rate fluctuations; technological advances, new products and patents attained
by competitors; challenges inherent in new product development, including
obtaining regulatory approvals; challenges to patents; significant adverse
litigation or government action; impact of business combinations; financial
distress and bankruptcies experienced by significant customers and suppliers;
changes to governmental laws and regulations and domestic and foreign health
care reforms; trends toward health care cost containment; increased scrutiny
of the health care industry by government agencies; changes in behavior and
spending patterns of purchasers of health care products and services;
financial instability of international economies and sovereign risk;
disruptions due to natural disasters; manufacturing difficulties or delays;
complex global supply chains with increasing regulatory requirements; and
product efficacy or safety concerns resulting in product recalls or regulatory
action. A further list and description of these risks, uncertainties and other
factors can be found in Exhibit 99 of Johnson & Johnson's Annual Report on
Form 10-K for the fiscal year ended December 30, 2012. Copies of this Form
10-K, as well as subsequent filings, are available online at www.sec.gov,
www.investor.jnj.com or on request from Johnson & Johnson.Johnson & Johnson
does not undertake to update any forward-looking statements as a result of new
information or future events or developments.)



Johnson &
Johnson and
Subsidiaries
Supplementary
Sales Data
(Unaudited;
Dollars in     SECOND QUARTER                                   SIX MONTHS
Millions)
                                                             
                                Percent                                          Percent
                                                            
                                Change                                           Change
               2013     2012    Total     Operations  Currency  2013     2012    Total   Operations  Currency
Sales to
customers by
segment of
business
Consumer
 U.S.       $        1,313   1.0    %  1.0         -         $        2,629   1.7   % 1.7         -
               1,326                                           2,674
            2,332    2,306   1.1       2.0         (0.9)     4,659    4,585   1.6     2.9         (1.3)
International
               3,658    3,619   1.1       1.7         (0.6)     7,333    7,214   1.6     2.4         (0.8)
Pharmaceutical
 U.S.       3,377    3,094   9.1       9.1         -         6,848    6,120   11.9    11.9        -
            3,648    3,197   14.1      16.5        (2.4)     6,945    6,304   10.2    12.4        (2.2)
International
               7,025    6,291   11.7      12.9        (1.2)     13,793   12,424  11.0    12.1        (1.1)
Med Devices &
Diagnostics
 U.S.       3,243    2,953   9.8       9.8         -         6,449    5,830   10.6    10.6        -
            3,951    3,612   9.4       13.7        (4.3)     7,807    7,146   9.2     12.9        (3.7)
International
               7,194    6,565   9.6       12.0        (2.4)     14,256   12,976  9.9     12.0        (2.1)
U.S.           7,946    7,360   8.0       8.0         -         15,971   14,579  9.5     9.5         -
International  9,931    9,115   9.0       11.8        (2.8)     19,411   18,035  7.6     10.2        (2.6)
Worldwide      $17,877  16,475  8.5    %  10.0        (1.5)     $35,382  32,614  8.5   % 9.9         (1.4)



Johnson &
Johnson and
Subsidiaries
Supplementary
Sales Data
(Unaudited;
Dollars in    SECOND QUARTER                                  SIX MONTHS
Millions)
                                        Percent                                         Percent
                                        Change                                          Change
              2013     2012     Total   Operations  Currency  2013     2012     Total   Operations  Currency
Sales to
customers by
geographic
area
U.S.          $        7,360    8.0   % 8.0         -         $15,971  14,579   9.5   % 9.5         -
              7,946
Europe        4,672    4,165    12.2    11.4        0.8       9,153    8,359    9.5     8.8         0.7
Western
Hemisphere    1,905    1,728    10.2    14.0        (3.8)     3,688    3,442    7.1     11.5        (4.4)
excluding
U.S.
Asia-Pacific, 3,354    3,222    4.1     11.0        (6.9)     6,570    6,234    5.4     11.4        (6.0)
Africa
International 9,931    9,115    9.0     11.8        (2.8)     19,411   18,035   7.6     10.2        (2.6)
Worldwide     $17,877  $16,475  8.5   % 10.0        (1.5)     $35,382  $32,614  8.5   % 9.9         (1.4)



Johnson & Johnson and
Subsidiaries
Condensed Consolidated
Statement of Earnings
(Unaudited; in Millions
Except Per Share        SECOND QUARTER
Figures)
                        2013                  2012                  Percent
                                    Percent               Percent   Increase
                        Amount      to Sales  Amount      to Sales  (Decrease)
Sales to customers      $         100.0     $         100.0     8.5
                        17,877                16,475
Cost of products sold   5,489       30.7      5,143       31.2      6.7
Selling, marketing and  5,376       30.1      4,965       30.1      8.3
administrative expenses
Research and            1,946       10.9      1,766       10.7      10.2
development expense
In-process research and -           -         429         2.6
development
Interest (income)       101         0.6       129         0.8
expense, net
Other (income) expense, 172         0.9       2,008       12.2
net
Earnings before
provision for taxes on  4,793       26.8      2,035       12.4      135.5
income
Provision for taxes on  960         5.4       627         3.9       53.1
income
Net earnings            $        21.4      $        8.5       172.2
                        3,833                 1,408
Net earnings per share  $                 $                 166.0
(Diluted)               1.33                  0.50
Average shares          2,893.0               2,798.2
outstanding (Diluted)
Effective tax rate      20.0      %           30.8      %
Adjusted earnings before provision
for taxes and net earnings (1)
 Earnings before       $                  $   
provision for taxes on  5,359       30.0      4,646       28.2      15.3
income
 Net earnings          $        24.0      $        22.1      17.7
                        4,289                 3,644
 Net earnings per      $                 $                 13.8
share (Diluted)         1.48                  1.30
 Effective tax rate    20.0      %           21.6      %
(1) See Reconciliation
of Non-GAAP Financial
Measures.



Johnson & Johnson and
Subsidiaries
Condensed Consolidated
Statement of Earnings
(Unaudited; in Millions
Except Per Share        SIX MONTHS
Figures)
                        2013                  2012                  Percent
                                    Percent               Percent   Increase
                        Amount      to Sales  Amount      to Sales  (Decrease)
Sales to customers      $         100.0     $         100.0     8.5
                        35,382                32,614
Cost of products sold   11,043      31.2      10,058      30.8      9.8
Selling, marketing and  10,599      30.0      9,980       30.6      6.2
administrative expenses
Research and            3,730       10.5      3,411       10.5      9.4
development expense
In-process research and 64          0.2       429         1.3
development
Interest (income)       205         0.6       259         0.8
expense, net
Other (income) expense, 687         1.9       1,397       4.3
net
Earnings before
provision for taxes on  9,054       25.6      7,080       21.7      27.9
income
Provision for taxes on  1,724       4.9       1,762       5.4       (2.2)
income
Net earnings            $        20.7      $        16.3      37.8
                        7,330                 5,318
Net earnings per share  $                 $                 33.5
(Diluted)               2.55                  1.91
Average shares          2,878.8               2,792.4
outstanding (Diluted)
Effective tax rate      19.0      %           24.9      %
Adjusted earnings before provision
for taxes and net earnings (1)
 Earnings before       $                   $   
provision for taxes on  10,429      29.5      9,574       29.4      8.9
income
 Net earnings          $        23.7      $        22.8      12.7
                        8,396                 7,448
 Net earnings per      $                 $                 9.4
share (Diluted)         2.92                  2.67
 Effective tax rate    19.5      %           22.2      %
(1) See Reconciliation
of Non-GAAP Financial
Measures.



Johnson & Johnson and
Subsidiaries
Reconciliation of Non-GAAP
Financial Measures
                           Second Quarter  % Incr.    Six Months     % Incr.
                                           /          YTD            /
(Dollars in Millions       2013     2012   (Decr.)    2013    2012   (Decr.)
Except Per Share Data)
Earnings before provision  $                         $      $ 
for taxes on income - as   4,793    2,035  135.5   %  9,054   7,080  27.9    %
reported
Intangible asset           -        939               -       939
write-downs
Litigation expenses        375      669               904     669
Synthes
integration/transaction    122      574               380     457
costs and currency related
In-process research and    -        429               64      429
development
DePuy ASR™Hip program      69       -                 82      -
Other                      -        -                 (55)    -
Earnings before provision  $                         $
for taxes on income - as   5,359    4,646  15.3    %  10,429  9,574  8.9     %
adjusted
Net Earnings - as reported $       1,408  172.2   %  $      5,318  37.8    %
                           3,833                      7,330
Intangible asset           -        717               -       717
write-downs
Litigation expenses        308      611               699     611
Synthes
integration/transaction    87       564               270     458
costs and currency related
In-process research and    -        344               42      344
development
DePuy ASR™Hip program      61       -                 91      -
Other                      -        -                 (36)    -
Net Earnings - as          $       3,644  17.7    %  $      7,448  12.7    %
adjusted                  4,289                      8,396
Diluted Net Earnings per   $      0.50   166.0   %  $     1.91   33.5    %
share - as reported        1.33                       2.55
Intangible asset           -        0.26              -       0.26
write-downs
Litigation expenses        0.10     0.22              0.24    0.22
Synthes
integration/transaction    0.03     0.20              0.09    0.16
costs and currency related
In-process research and    -        0.12              0.02    0.12
development
DePuy ASR™Hip program      0.02     -                 0.03    -
Other                      -        -                 (0.01)  -
Diluted Net Earnings per   $      1.30   13.8    %  $     2.67   9.4     %
share - as adjusted       1.48                       2.92
The Company believes investors gain additional perspective of
underlying business trends and results by providing a measure of
earnings before provision for taxes
on income, net earnings and diluted net earnings per share
that excludes special items in order to evaluate ongoing
business operations.



           REPORTED SALES vs. PRIOR PERIOD ($MM)
           SECOND QUARTER                               SIX MONTHS
                         % Change                                     % Change
            2013   2012  Reported Operational Currency   2013   2012  Reported Operational Currency
                                  ^(1)                                         ^(1)
CONSUMER
SEGMENT
^(2) (4)
BABY CARE
            $                                          $  
US               106   0.0%     0.0%        -               205   2.0%     2.0%        -
            106                                         209
Intl        480    472   1.7%     3.8%        -2.1%      941    913   3.1%     5.7%        -2.6%
WW          586    578   1.4%     3.1%        -1.7%      1,150  1,118 2.9%     5.0%        -2.1%
ORAL CARE
US          149    159   -6.3%    -6.3%       -          307    314   -2.2%    -2.2%       -
Intl        257    249   3.2%     4.3%        -1.1%      502    481   4.4%     5.8%        -1.4%
WW          406    408   -0.5%    0.2%        -0.7%      809    795   1.8%     2.6%        -0.8%
OTC ^(3)
US          290    247   17.4%    17.4%       -          644    538   19.7%    19.7%       -
Intl        641    636   0.8%     0.9%        -0.1%      1,330  1,296 2.6%     3.0%        -0.4%
WW          931    883   5.4%     5.4%        0.0%       1,974  1,834 7.6%     7.9%        -0.3%
SKIN CARE
US          463    471   -1.7%    -1.7%       -          916    924   -0.9%    -0.9%       -
Intl        445    442   0.7%     1.0%        -0.3%      894    896   -0.2%    0.3%        -0.5%
WW          908    913   -0.5%    -0.4%       -0.1%      1,810  1,820 -0.5%    -0.3%       -0.2%
WOMEN'S
HEALTH
US          84     80    5.0%     5.0%        -          165    173   -4.6%    -4.6%       -
Intl        327    322   1.6%     3.4%        -1.8%      647    638   1.4%     4.1%        -2.7%
WW          411    402   2.2%     3.6%        -1.4%      812    811   0.1%     2.2%        -2.1%
WOUND
CARE/OTHER
^(3)
US          234    250   -6.4%    -6.4%       -          433    475   -8.8%    -8.8%       -
Intl        182    185   -1.6%    -1.4%       -0.2%      345    361   -4.4%    -4.0%       -0.4%
WW          416    435   -4.4%    -4.3%       -0.1%      778    836   -6.9%    -6.7%       -0.2%
TOTAL
CONSUMER
US          1,326  1,313 1.0%     1.0%        -          2,674  2,629 1.7%     1.7%        -
Intl        2,332  2,306 1.1%     2.0%        -0.9%      4,659  4,585 1.6%     2.9%        -1.3%
            $                                          $  
WW                3,619 1.1%     1.7%        -0.6%            7,214 1.6%     2.4%        -0.8%
            3,658                                        7,333
See
footnotes
at end of
schedule

Supplemental Sales Information
                               2012                        2013
                                Q1   Q2  Q3  Q4    FY      Q1
OTC
US                              291  247 263 273   1,074   354
Intl                            660  636 653 743   2,692   689
WW                              951  883 916 1,016 3,766   1,043
WOUND CARE/OTHER
US                              225  250 214 195   884     199
Intl                            176  185 163 152   676     163
WW                              401  435 377 347   1,560   362



               REPORTED SALES vs. PRIOR PERIOD ($MM)
               SECOND QUARTER                               SIX MONTHS
                             % Change                                     % Change
                2013   2012  Reported Operational Currency   2013   2012  Reported Operational Currency
                                      ^(1)                                         ^(1)
PHARMACEUTICAL
SEGMENT ^(2)
(4)
IMMUNOLOGY
                $                                          $  
US                    1,471 7.3%     7.3%        -                2,924 10.0%    10.0%       -
                1,578                                        3,217
Intl            663    448   48.0%    51.5%       -3.5%      1,228  890   38.0%    40.9%       -2.9%
WW              2,241  1,919 16.8%    17.6%       -0.8%      4,445  3,814 16.5%    17.2%       -0.7%
REMICADE
US             926    890   4.0%     4.0%        -          1,896  1,772 7.0%     7.0%        -
US Exports      332    366   -9.3%    -9.3%       -          681    744   -8.5%    -8.5%       -
^(5)
Intl            414    267   55.1%    58.2%       -3.1%      695    28    31.6%    34.0%       -2.4%
WW              1,672  1,523 9.8%     10.3%       -0.5%      3,272  3,044 7.5%     7.9%        -0.4%
SIMPONI
US              87     63    38.1%    38.1%       -          181    127   42.5%    42.5%       -
Intl            88     62    41.9%    48.3%       -6.4%      231    114   *        *           -4.5%
WW              175    125   40.0%    43.2%       -3.2%      412    241   71.0%    73.5%       -2.5%
STELARA
US              233    152   53.3%    53.3%       -          459    281   63.3%    63.3%       -
Intl            138    96    43.8%    45.4%       -1.6%      258    188   37.2%    38.4%       -1.2%
WW              371    248   49.6%    50.2%       -0.6%      717    469   52.9%    53.4%       -0.5%
OTHER
IMMUNOLOGY
US              -      -     -        -           -          -      -     -        -           -
Intl            23     23    0.0%     1.1%        -1.1%      44     60    -26.7%   -26.1%      -0.6%
WW              23     23    0.0%     1.1%        -1.1%      44     60    -26.7%   -26.1%      -0.6%
INFECTIOUS
DISEASES
US              259    237   9.3%     9.3%        -          497    479   3.8%     3.8%        -
Intl            711    551   29.0%    30.2%       -1.2%      1,288  1,064 21.1%    22.2%       -1.1%
WW              970    788   23.1%    23.9%       -0.8%      1,785  1,543 15.7%    16.5%       -0.8%
INCIVO
US              -      -     -        -           -          -      -     -        -           -
Intl            172    102   68.6%    71.8%       -3.2%      334    234   42.7%    45.4%       -2.7%
WW              172    102   68.6%    71.8%       -3.2%      334    234   42.7%    45.4%       -2.7%
INTELENCE
US              44     42    4.8%     4.8%        -          91     85    7.1%     7.1%        -
Intl            59     49    20.4%    21.0%       -0.6%      101    86    17.4%    18.0%       -0.6%
WW              103    91    13.2%    13.5%       -0.3%      192    171   12.3%    12.6%       -0.3%
PREZISTA
US              196    166   18.1%    18.1%       -          363    326   11.3%    11.3%       -
Intl            239    207   15.5%    16.0%       -0.5%      439    371   18.3%    18.7%       -0.4%
WW              435    373   16.6%    16.9%       -0.3%      802    697   15.1%    15.3%       -0.2%
OTHER
INFECTIOUS
DISEASES
US              19     29    -34.5%   -34.5%      -          43     68    -36.8%   -36.8%      -
Intl            241    193   24.9%    25.8%       -0.9%      414    373   11.0%    11.9%       -0.9%
WW              260    222   17.1%    17.9%       -0.8%      457    441   3.6%     4.3%        -0.7%



                         REPORTED SALES vs. PRIOR PERIOD ($MM)
                         SECOND QUARTER                               SIX MONTHS
                                       % Change                                     % Change
                          2013   2012  Reported Operational Currency   2013   2012  Reported Operational Currency
                                                ^(1)                                         ^(1)
NEUROSCIENCE
US                        626    658   -4.9%    -4.9%       -          1,372  1,332 3.0%     3.0%        -
Intl                      1,054  1,056 -0.2%    3.8%        -4.0%      2,052  2,029 1.1%     4.6%        -3.5%
WW                        1,680  1,714 -2.0%    0.4%        -2.4%      3,424  3,361 1.9%     4.0%        -2.1%
CONCERTA/METHYLPHENIDATE
US                        85     146   -41.8%   -41.8%      -          224    343   -34.7%   -34.7%      -
Intl                      130    122   6.6%     8.9%        -2.3%      247    233   6.0%     7.9%        -1.9%
WW                        215    268   -19.8%   -18.7%      -1.1%      471    576   -18.2%   -17.4%      -0.8%
INVEGA
US                        76     76    0.0%     0.0%        -          147    145   1.4%     1.4%        -
Intl                      74     66    12.1%    18.3%       -6.2%      135    118   14.4%    19.9%       -5.5%
WW                        150    142   5.6%     8.4%        -2.8%      282    263   7.2%     9.7%        -2.5%
INVEGA SUSTENNA/ XEPLION
US                        158    120   31.7%    31.7%       -          322    220   46.4%    46.4%       -
Intl                      132    75    76.0%    75.0%       1.0%       252    136   85.3%    84.4%       0.9%
WW                        290    195   48.7%    48.3%       0.4%       574    356   61.2%    60.9%       0.3%
RISPERDAL CONSTA
US                        107    110   -2.7%    -2.7%       -          213    223   -4.5%    -4.5%       -
Intl                      229    245   -6.5%    -3.7%       -2.8%      458    493   -7.1%    -4.9%       -2.2%
WW                        336    355   -5.4%    -3.5%       -1.9%      671    716   -6.3%    -4.8%       -1.5%
OTHER NEUROSCIENCE
US                        200    206   -2.9%    -2.9%       -          466    401   16.2%    16.2%       -
Intl                      489    548   -10.8%   -5.5%       -5.3%      960    1,049 -8.5%    -3.7%       -4.8%
WW                        689    754   -8.6%    -4.8%       -3.8%      1,426  1,450 -1.7%    1.8%        -3.5%
ONCOLOGY
US                        206    119   73.1%    73.1%       -          405    226   79.2%    79.2%       -
Intl                      679    467   45.4%    48.1%       -2.7%      1,274  956   33.3%    35.8%       -2.5%
WW                        885    586   51.0%    53.2%       -2.2%      1,679  1,182 42.0%    44.0%       -2.0%
VELCADE
US                        -      -     -        -           -          -      -     -        -           -
Intl                      379    318   19.2%    22.7%       -3.5%      732    671   9.1%     12.1%       -3.0%
WW                        379    318   19.2%    22.7%       -3.5%      732    671   9.1%     12.1%       -3.0%
ZYTIGA
US                        174    113   54.0%    54.0%       -          335    213   57.3%    57.3%       -
Intl                      221    119   85.7%    85.2%       0.5%       404    219   84.5%    84.4%       0.1%
WW                        395    232   70.3%    70.0%       0.3%       739    432   71.1%    71.1%       0.0%
OTHER ONCOLOGY
US                        32     6     *        *           -          70     13    *        *           -
Intl                      79     30    *        *           -7.4%      138    66    *        *           -6.0%
WW                        111    36    *        *           -6.1%      208    79    *        *           -5.0%



               REPORTED SALES vs. PRIOR PERIOD ($MM)
               SECOND QUARTER                               SIX MONTHS
                             % Change                                       % Change
                2013   2012  Reported Operational Currency   2013    2012   Reported Operational Currency
                                      ^(1)                                           ^(1)
TOTAL OTHER
US              708    609   16.3%    16.3%       -          1,357   1,159  17.1%    17.1%       -
Intl            541    675   -19.9%   -19.9%      0.0%       1,103   1,365  -19.2%   -18.6%      -0.6%
WW              1,249  1,284 -2.7%    -2.7%       0.0%       2,460   2,524  -2.5%    -2.2%       -0.3%
ACIPHEX/PARIET
US              97     104   -6.7%    -6.7%       -          200     200    0.0%     0.0%        -
Intl            59     128   -53.9%   -54.0%      0.1%       108     254    -57.5%   -57.3%      -0.2%
WW              156    232   -32.8%   -32.8%      0.0%       308     454    -32.2%   -32.1%      -0.1%
PROCRIT/EPREX
US              190    232   -18.1%   -18.1%      -          423     436    -3.0%    -3.0%       -
Intl            145    169   -14.2%   -14.6%      0.4%       290     341    -15.0%   -15.3%      0.3%
WW              335    401   -16.5%   -16.7%      0.2%       713     777    -8.2%    -8.3%       0.1%
XARELTO
US              189    49    *        *           -          347     76     *        *           -
Intl            -      -     -        -           -          -       -      -        -           -
WW              189    49    *        *           -          347     76     *        *           -
OTHER
US              232    224   3.6%     3.6%        -          387     447    -13.4%   -13.4%      -
Intl            337    378   -10.8%   -10.5%      -0.3%      705     770    -8.4%    -7.4%       -1.0%
WW              569    602   -5.5%    -5.3%       -0.2%      1,092   1,217  -10.3%   -9.7%       -0.6%
TOTAL
PHARMACEUTICAL
US              3,377  3,094 9.1%     9.1%        -          6,848   6,120  11.9%    11.9%       -
Intl            3,648  3,197 14.1%    16.5%       -2.4%      6,945   6,304  10.2%    12.4%       -2.2%
                $                                          $  
WW                    6,291 11.7%    12.9%       -1.2%      13,793  12,424 11.0%    12.1%       -1.1%
                7,025



                 REPORTED SALES vs. PRIOR PERIOD ($MM)
                 SECOND QUARTER                               SIX MONTHS
                               % Change                                       % Change
                  2013   2012  Reported Operational Currency   2013    2012   Reported Operational Currency
                                        ^(1)                                           ^(1)
MEDICAL DEVICES
AND DIAGNOSTICS
^(2)
CARDIOVASCULAR
CARE
                  $                                          $  
US                     195   4.6%     4.6%        -                371    8.4%     8.4%        -
                  204                                         402
Intl              325    309   5.2%     9.6%        -4.4%      640     615    4.1%     8.0%        -3.9%
WW                529    504   5.0%     7.7%        -2.7%      1,042   986    5.7%     8.1%        -2.4%
DIABETES CARE
US                259    337   -23.1%   -23.1%      -          542     689    -21.3%   -21.3%      -
Intl              330    336   -1.8%    -0.5%       -1.3%      647     654    -1.1%    0.2%        -1.3%
WW                589    673   -12.5%   -11.8%      -0.7%      1,189   1,343  -11.5%   -10.9%      -0.6%
DIAGNOSTICS
US                241    258   -6.6%    -6.6%       -          489     511    -4.3%    -4.3%       -
Intl              242    256   -5.5%    -1.5%       -4.0%      471     515    -8.5%    -4.7%       -3.8%
WW                483    514   -6.0%    -4.0%       -2.0%      960     1,026  -6.4%    -4.5%       -1.9%
INFECTION
PREVENTION/OTHER
US                95     99    -4.0%    -4.0%       -          180     215    -16.3%   -16.3%      -
Intl              139    131   6.1%     12.3%       -6.2%      266     259    2.7%     8.2%        -5.5%
WW                234    230   1.7%     5.2%        -3.5%      446     474    -5.9%    -2.9%       -3.0%
ORTHOPAEDICS
US               1,274  873   45.9%    45.9%       -          2,535   1,656  53.1%    53.1%       -
Intl              1,111  755   47.2%    52.4%       -5.2%      2,235   1,465  52.6%    56.3%       -3.7%
WW                2,385  1,628 46.5%    48.9%       -2.4%      4,770   3,121  52.8%    54.5%       -1.7%
SPECIALTY
SURGERY
US                331    336   -1.5%    -1.5%       -          650     663    -2.0%    -2.0%       -
Intl              325    310   4.8%     7.5%        -2.7%      633     611    3.6%     6.2%        -2.6%
WW                656    646   1.5%     2.8%        -1.3%      1,283   1,274  0.7%     1.9%        -1.2%
SURGICAL CARE
US                577    602   -4.2%    -4.2%       -          1,108   1,195  -7.3%    -7.3%       -
Intl              1,011  1,038 -2.6%    0.6%        -3.2%      1,988   2,070  -4.0%    -1.0%       -3.0%
WW                1,588  1,640 -3.2%    -1.2%       -2.0%      3,096   3,265  -5.2%    -3.3%       -1.9%
VISION CARE
US                262    253   3.6%     3.6%        -          543     530    2.5%     2.5%        -
Intl              468    477   -1.9%    6.4%        -8.3%      927     957    -3.1%    4.1%        -7.2%
WW                730    730   0.0%     5.4%        -5.4%      1,470   1,487  -1.1%    3.5%        -4.6%
TOTAL MEDICAL
DEVICES AND
DIAGNOSTICS
US                3,243  2,953 9.8%     9.8%        -          6,449   5,830  10.6%    10.6%       -
Intl              3,951  3,612 9.4%     13.7%       -4.3%      7,807   7,146  9.2%     12.9%       -3.7%
                  $                                          $  
WW                      6,565 9.6%     12.0%       -2.4%      14,256  12,976 9.9%     12.0%       -2.1%
                  7,194



* Percentage greater than 100%
(1) Operational growth excludes the effect of currency
(2) Select areas (unaudited)
(3) Nutritionals now reflected in Wound Care/Other, previously reported in
OTC/Nutritionals
(4) Prior year amounts have been reclassified to conform to current year
product disclosure
(5) Reported as U.S. sales

SOURCE Johnson & Johnson

Website: http://www.jnj.com
Contact: Press Contacts: Ernie Knewitz, (732) 524-6623, (917) 697-2318 (M), Al
Wasilewski(732) 524-1130, (732) 447-5918 (M), Investor Contacts: Louise
Mehrotra, (732) 524-6491, Stan Panasewicz, (732) 524-2524
 
Press spacebar to pause and continue. Press esc to stop.